Cigna Group (CI) continues to draw investor attention, with the stock last closing at US$282.08 and recent returns showing mixed movements over the past week, month, and past 3 months.

Looking beyond the recent pullback, Cigna Group’s share price has recorded a 6.1% 3 month share price return and a modest 1.1% year to date share price return. The 1 year total shareholder return is down 9.0%, suggesting momentum has softened compared with its longer term 3 year and 5 year total shareholder returns of 8.0% and 28.9% respectively.

If you are comparing Cigna Group with other opportunities in the sector, this could be a good moment to scan for companies riding similar healthcare trends via 38 healthcare AI stocks

So, with Cigna Group trading at US$282.08 alongside an indicated 66.5% intrinsic discount and a 20.7% gap to analyst targets, is the stock still undervalued, or is the market already accounting for future growth?

Most Popular Narrative: 17.3% Undervalued

The most followed narrative currently places Cigna Group’s fair value at $340.92, above the last close of $282.08, framing a valuation gap that hinges on future earnings and margin assumptions.

Cigna's ongoing innovation in digital health and AI-powered tools (e.g., virtual assistant, advanced specialty services) allows it to enhance care coordination and operational efficiency, which should help contain costs, improve the medical care ratio, and support higher net margins over time.

The fair value hinges on a tight set of revenue and profit margin assumptions. It leans heavily on earnings expansion and a higher future earnings multiple. Curious which specific growth and margin paths have been baked into that story, and how they connect back to today’s share price?

Result: Fair Value of $340.92 (UNDERVALUED)

However, Cigna Group’s heavy reliance on the Evernorth PBM model and ongoing regulatory scrutiny around drug pricing and billing could pressure margins and challenge this upside narrative.

Next Steps

With Cigna Group attracting both optimism and concern, it makes sense to check the underlying data yourself and decide how the risk reward balance stacks up in your view with the help of 6 key rewards and 1 important warning sign

Looking for more investment ideas beyond Cigna Group?

If you are weighing Cigna Group against other possibilities, it can help to line up a few fresh ideas so you are not relying on a single story.

• Spot potential value opportunities early by scanning screener containing 19 high quality undiscovered gems, which combine solid fundamentals with room for a re rating.
• Strengthen the core of your portfolio by checking companies in the solid balance sheet and fundamentals stocks screener (48 results), which may better withstand shocks.
• Build a steadier income stream by reviewing 7 dividend fortresses, which focus on higher yields with supporting financials.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.